Evidence map›Paper›PMID 42398006›Full record

ArticleArhiv za higijenu rada i toksikologiju2026

Combined

İbrahim Gecili, Sıdıka Genç, Ahmet Hacımüftüoğlu, Adem Güner, Esmanur Niğde, Kübra Karabulut, Dündar Okan Yıllar, Ali Taghizadehehghalehjoughi, Abdelaty Mostafa Abdelaty Hassibelnaby

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Arhiv za higijenu rada i toksikologiju, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

İbrahim GeciliIstanbul Beykent University Faculty of Medicine, Department of Medical Pharmacology, Istanbul, Turkey.ORCID https://orcid.org/0000-0001-6771-6669
Sıdıka GençBilecik Şeyh Edebali University Faculty of Medicine, Department of Medical Pharmacology, Bilecik, Turkey.
Ahmet HacımüftüoğluAtatürk University Medical Faculty, Department of Medical Pharmacology, Erzurum, Turkey.
Adem GünerSinop University Faculty of Health Sciences, Department of Occupational Health and Safety, Sinop, Turkey.
Esmanur NiğdeBilecik Şeyh Edebali University Faculty of Medicine, Department of Medical Pharmacology, Bilecik, Turkey.
Kübra KarabulutBilecik Şeyh Edebali University Faculty of Medicine, Department of Medical Pharmacology, Bilecik, Turkey.
Dündar Okan YıllarIstanbul Beykent University Faculty of Medicine, Department of Medical Pharmacology, Istanbul, Turkey.
Ali TaghizadehehghalehjoughiBilecik Şeyh Edebali University Faculty of Medicine, Department of Medical Pharmacology, Bilecik, Turkey.
Abdelaty Mostafa Abdelaty HassibelnabyAtatürk University Medical Faculty, Department of Medical Pharmacology, Erzurum, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Limited efficacy of glioblastoma treatment with temozolomide (TMZ) due to resistance has prompted researchers to look for adjuvants capable of enhancing TMZ-associated cytotoxicity. The aim of our

Indexed as

Antineoplastic Agents, AlkylatingApoptosisCell SurvivalDacarbazineGlioblastomaOxidative StressTemozolomideCell Line, TumorHumansSignal TransductionAntineoplastic Agents, AlkylatingDacarbazineTemozolomidecancer therapychemotherapycitotoksičnostcytotoxicityfatty acidsglioblastomakemoterapijamasne kiselineoksidacijski stresoxidative stressterapija raka

Identifiers

PMID42398006
PMCPMC13331364

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.